Literature DB >> 20856204

Harnessing the immune response to treat cancer.

H J Steer1, R A Lake, A K Nowak, B W S Robinson.   

Abstract

It is well established that the immune system has the capacity to attack malignant cells. During malignant transformation cells acquire numerous molecular and biochemical changes that render them potentially vulnerable to immune cells. Yet it is self-evident that a growing tumour has managed to evade these host defence mechanisms. The exact ways in which the immune system interacts with tumour cells and how cancers are able to escape immunological eradication have only recently started to be fully elucidated. Understanding the relationship between the tumour and the anti-tumour immune response and how this can be altered with conventional treatments and immune-targeted therapies is crucial to developing new treatments for patients with cancer. In this review, focusing on the anti-tumour T-cell response, we summarize our understanding of how tumours, cancer treatments and the immune system interact, how tumours evade the immune response and how this process could be manipulated for the benefit of patients with cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20856204     DOI: 10.1038/onc.2010.437

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  30 in total

1.  Infiltrating CTLs are bothered by HLA-E on tumors.

Authors:  Marloes J M Gooden; Thorbald van Hall
Journal:  Oncoimmunology       Date:  2012-01-01       Impact factor: 8.110

2.  Increasing vaccine potency through exosome antigen targeting.

Authors:  Zachary C Hartman; Junping Wei; Oliver K Glass; Hongtao Guo; Gangjun Lei; Xiao-Yi Yang; Takuya Osada; Amy Hobeika; Alain Delcayre; Jean-Bernard Le Pecq; Michael A Morse; Timothy M Clay; Herbert K Lyerly
Journal:  Vaccine       Date:  2011-10-12       Impact factor: 3.641

Review 3.  Targeting regulatory T cells in cancer.

Authors:  William L Byrne; Kingston H G Mills; James A Lederer; Gerald C O'Sullivan
Journal:  Cancer Res       Date:  2011-11-08       Impact factor: 12.701

Review 4.  The Future of Immunotherapy in the Treatment of Small Cell Lung Cancer.

Authors:  Leora Horn; Martin Reck; David R Spigel
Journal:  Oncologist       Date:  2016-06-27

5.  CpG expedites regression of local and systemic tumors when combined with activatable nanodelivery.

Authors:  Azadeh Kheirolomoom; Elizabeth S Ingham; Lisa M Mahakian; Sarah M Tam; Matthew T Silvestrini; Spencer K Tumbale; Josquin Foiret; Neil E Hubbard; Alexander D Borowsky; William J Murphy; Katherine W Ferrara
Journal:  J Control Release       Date:  2015-10-22       Impact factor: 9.776

6.  Transcriptional profiling of peripheral blood in pancreatic adenocarcinoma patients identifies diagnostic biomarkers.

Authors:  Octavio Caba; Jose Prados; Raúl Ortiz; Cristina Jiménez-Luna; Consolación Melguizo; Pablo J Alvarez; Juan R Delgado; Antonio Irigoyen; Ignacio Rojas; Javier Pérez-Florido; Carolina Torres; Sonia Perales; Ana Linares; Antonia Aránega
Journal:  Dig Dis Sci       Date:  2014-07-29       Impact factor: 3.199

7.  A bispecific nanobody approach to leverage the potent and widely applicable tumor cytolytic capacity of Vγ9Vδ2-T cells.

Authors:  Renée C G de Bruin; John P Veluchamy; Sinéad M Lougheed; Famke L Schneiders; Silvia Lopez-Lastra; Roeland Lameris; Anita G Stam; Zsolt Sebestyen; Jürgen Kuball; Carla F M Molthoff; Erik Hooijberg; Rob C Roovers; James P Di Santo; Paul M P van Bergen En Henegouwen; Henk M W Verheul; Tanja D de Gruijl; Hans J van der Vliet
Journal:  Oncoimmunology       Date:  2017-10-20       Impact factor: 8.110

8.  TLR4-mediated immunomodulatory properties of the bacterial metalloprotease arazyme in preclinical tumor models.

Authors:  Felipe V Pereira; Amanda C L Melo; Filipe M de Melo; Diego Mourão-Sá; Priscila Silva; Rodrigo Berzaghi; Carolina C A Herbozo; Jordana Coelho-Dos-Reis; Jorge A Scutti; Clarice S T Origassa; Rosana M Pereira; Luis Juliano; Maria Aparecida Juliano; Adriana K Carmona; Niels O S Câmara; Moriya Tsuji; Luiz R Travassos; Elaine G Rodrigues
Journal:  Oncoimmunology       Date:  2016-05-05       Impact factor: 8.110

9.  Examining T cells at vaccine sites of tumor-bearing hosts provides insights to dysfunctional T-cell immunity.

Authors:  Kristen M Barr; Weiqing Jing; William H D Hallett; Jill A Gershan; Bryon D Johnson
Journal:  J Immunother       Date:  2013-01       Impact factor: 4.456

10.  Enhancing Dendritic Cell-based Immunotherapy with IL-2/Monoclonal Antibody Complexes for Control of Established Tumors.

Authors:  Marie T Kim; Martin J Richer; Brett P Gross; Lyse A Norian; Vladimir P Badovinac; John T Harty
Journal:  J Immunol       Date:  2015-09-25       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.